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A B S T R A C T
Rationale: Vagus nerve stimulation (VNS) is a frequently used treatment for patients with refractory
epilepsy who are unsuitable candidates for epilepsy surgery. There has been a steady evolution in VNS
technology, as generators’ volumes have become smaller and battery life expectancy longer. This pilot
study is an open-label retrospective study that describes our experience with the latest commercially
available generator, i.e. the VNS TherapyTM Demipulse Model 103. Treatment efﬁcacy and side effects, as
well as technical and practical enhancements useful for the patient and for the medical staff are
discussed in this study.
Methods: Twenty patients (11F/9M) with a mean age of 40 years (range 8–61), who were considered
unsuitable candidates for resective surgery, were implantedwith a VNS TherapyTMDemipulseModel 103.
Mean monthly seizure frequency reduction and side effects were evaluated 1 year after implantation.
Results: Mean monthly seizure frequency decreased signiﬁcantly from 54 seizures/month (SEM 30;
range 1–555) before treatment to 33 (SEM24, range 0–445) following 12months of treatment (p < 0.05).
Seven patients (39%) were considered responders with a reduction in seizure frequency of more than
50%. One of those seven patients became seizure free. Side effects were stimulation-related tingling
sensation in the throat and/or hoarseness, a painful sensation in the left neck or ear region and a lead
breakage In addition; one case of SUDEP was reported.
Conclusion: Patients treated with VNS TherapyTM Demipulse generators proved to have a signiﬁcant
decrease in seizure frequency. In this patient group, VNSwaswell tolerated. Themain technical advances
are the decrease in size and improved options for battery life follow-up.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Vagus nerve stimulation (VNS) is indicated in patients with
medically or surgically refractory epilepsy. More than 50,000
patients worldwide have been implanted with VNS therapyTM
devices since 1989. Initially, efﬁcacy of VNS for refractory epilepsy
was studied in the randomised double-blind placebo-controlled
E03 and E05 studies, which included 114 and 198 patients with a
follow-up of 3 months.1,2 In these studies, seizure frequency
reduction was compared between a high, so-called effective
stimulation group and a low, so-called placebo stimulation group.
The E03 study found a decrease in seizures of 24% in the high
stimulation group versus 6% in the low stimulation group, while
the E05 study found a 28% decrease in seizure frequency in the high
stimulation group versus 15% in the low stimulation group.1,2
Prospective and retrospective long-term open-label studies* Corresponding author. Tel.: +32 93325795; fax: +32 93326517.
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1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.07.011conﬁrmed VNS efﬁcacy and safety in adults and children with
refractory epilepsy.3–11
In parallel with the increasing amount of clinical data, there has
been a steady evolution in VNS technology, as the size of the
generator has become smaller (Fig. 1) and battery life expectancy
has increased at each new generator release.
This pilot study is an open-label retrospective study that
describes our experience with the latest commercially available
generator, i.e. the VNS TherapyTM Demipulse Model 103. Treat-
ment efﬁcacy and side effects, as well as technical and practical
enhancements useful for neurologists, neurosurgeons and for the
patient, are discussed in this study. This study is the ﬁrst to date to
report clinical experience with Demipulse generators.
2. Patients and methods
2.1. Patient population and presurgical evaluation
Between 1/6/2007 and 1/12/2009, 40 patients were implanted
with a VNS device (Cyberonics1, Houston, USA) at the Ghentvier Ltd. All rights reserved.
Fig. 1. Volume reduction of VNS generators over time.
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epilepsy and underwent long-term video-EEG monitoring for
seizure detection, 3 T brain MRI and PET scan as part of the
presurgical evaluation. All patients were considered unsuitable
candidates for resective surgery, either because the epileptic focus
remained unidentiﬁed, or because it was located in functional
cortex. Subsequently theywere offered treatmentwith VNS. For the
purpose of this study, medical records of patients implanted with a
VNS therapyTMDemipulseModel 103were evaluated. Patients with
apost-implantation follow-upof at least1 yearwere included in this
study. Additionally, a documentation of seizure frequency before
implantation and at maximal follow-up was required.
2.2. Implantation procedure
The system was implanted under general anaesthesia via two
short incisions. The ﬁrst incisionwas placed in a skin fold at the left
base of the neck, about 3 cm above the clavicle and across the
medial border of the sternocleidomastoid muscle. The left vagus
nerve was searched for between the common carotid artery and
the internal jugular vein, and exposed over a distance of 3 cm.
Using optical magniﬁcation, the helical tether and the two helical
electrodeswerewrapped around the nerve. The leadwas carried to
the surface in smooth loops and anchored twice, both to the deep
and to the superﬁcial cervical fascia. Through a second, also
transverse, incision below the left clavicle on the mamillary line, a
small epifascial pouch was shaped in which the pulse generator
(Cyberonics Demipulse, model 103 or 104) was placed. The lead
was subcutaneously tunneled from the ﬁrst to the second incision
and plugged into the pulse generator. The system was telemetri-
cally veriﬁed before the pulse generator was anchored to the
pectoral fascia and the wounds were closed.
2.3. Ramping-up procedure and stimulation parameters
Stimulation was initiated 2–4 weeks after surgery at the
epilepsy clinic. Stimulation intensity was gradually increased over
the next months with steps of 0.25 mA until seizure control was
reached or side effects appeared. The other stimulation parameters
were programmed as follows: pulse width 250–500 ms; frequency
20–30 Hz; on/off cycle 30 s on/10 min off or 30 s on/5 min off. As
part of normal clinical practice in patients treated with VNS at the
Ghent University Hospital, antiepileptic drug (AED) treatment was
preferably left unchanged during the ﬁrst 12 months of follow-up.
2.4. Outcome measures
The clinical data collected for this study included: gender and
age at time of implantation; type of epilepsy; mean monthlyseizure frequency before implantation and at maximal follow-up;
number of antiepileptic drugs taken before implantation and at
maximal follow-up; stimulation intensity at maximum follow-up.
In addition, properties of the surgical implantation procedure as
well as user friendly characteristics for neurologist and patients
were assessed.
Monthly seizure frequency pre-VNS was based on seizure
frequency reported 1 month before date of surgery. Meanmonthly
seizure frequency post-VNS resulted from an average of two to
three consecutive months at maximum follow-up.
Type of epilepsy was based on clinical semiology of the seizures
and ictal and interictal electroencephalographic recordings.
Primary outcome measures included reduction in mean
monthly seizure frequency and the percentage of patients with
a seizure frequency reduction of 50% or more (responder rate).
Secondary outcome measures were the changes in number of
concomitant AEDs taken at maximum follow-up compared to
before stimulation and stimulation output at maximum follow-up.
Outcome measures were ﬁrst calculated for the entire study
group. Subsequently, the study population was divided into two
groups: responders (seizure frequency reductionof50%ormore) and
non-responders (seizure frequency reduction between of less than
50%). Outcome parameters were assessed for the two groups
separately.
2.5. Ethical approval
This retrospective study was approved by the Ethical Commit-
tee of Ghent University Hospital (EC 2005/238 and EC 2009/604).
Informed consent was obtained from all patients.
2.6. Statistical analysis
Group mean differences in percentage of reductions in seizure
frequency and differences in mean monthly seizure frequencies
were tested non-parametrically. Statistical signiﬁcance was set on
p < 0.05. All calculations were performed using SPSS 15.0.
3. Results
3.1. Patient population
Twenty patients (11 females, 9 males) with a mean age of 40
years (range 8–61)were included in the study. Sixteen patients had
localised epilepsy with complex partial seizures with or without
secondary generalisation. Four patients had generalised epilepsy
with tonic clonic seizures, absences or myoclonic seizures. Two
patients had a follow-up of 6 and 8 months due to early
discontinuation of VNS therapy (1 sudden unexplained death in
Table 1
Overview of primary and secondary outcome parameters in patient population.
Seizure reduction50% Seizure reduction50%
N=7 N=11
Mean age at implantation (years) 34 (range 21–56) 32 (8–49)
Mean follow-up (months) 12 12
Mean seizure frequency/month pre-VNS (n) 42 (range 7–150) 62 (1–555)
Mean seizure frequency/month post-VNS (n) 4 (range 0–12.5) 51 (1–445)
Mean seizure reduction (%) 84 13
Number of AED before (n) 3 (2–5) 3 (3–4)
Number of AED after (n) 3 (2–5) 3 (2–5)
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excluded from further statistical analysis.
3.2. Seizure frequency reduction and responder rate (Table 1)
Mean monthly seizure frequency before implantation was 54
seizures/month (SEM 30, range 1–555), mean monthly seizure
frequency atmaximum follow-upwas 33 seizures/month (SEM 24,
range 0–445) (Wilcoxon Signed Ranks test, <0.05).
Seven patients (39%) were considered responders with a
reduction in seizure frequency of more than 50%. One of those
seven patients became seizure free. Eleven patients (61%)were non-
responders (reduction in seizure frequency of less than 50%). In the
non-responder group, three patients (16%) respondedwith a seizure
frequency reduction between 30 and 50%, two patients (11%)
responded with a seizure frequency reduction of less than 30%, ﬁve
patients (28%) experienced no change in seizure frequency and one
patient reported a small increase in seizure frequency. Responders
started to respond to their VNS treatment at month 7 after date of
implantation, while no effect was seen over time in the non-
responder group (see Fig. 2) (Wilcoxon Signed Ranks test, p< 0.05).
3.3. Comparison between responders, partial responders and non-
responders
There were no signiﬁcant differences regarding seizure
frequency before VNS, mean age at time of implantation and
number of AEDs before implantation, between the responder and
non-responder group (Table 1).
Themean stimulation output current atmaximal follow-upwas
1.79 mA (range 0.75–2.5 mA) (Fig. 3). Responders had a lower
mean stimulation output at maximal follow-up (1.64 mA, rangeFig. 2. Evolution of mean monthly seizure frequency in responders and partial
responders compared to non-responders over time. Responders started to respond
to their VNS treatment at month 7 after date of implantation.0.75–2.25 mA) in comparison to non-responders (1.88 mA, range
1.5–2.5 mA), although these differences were not statistically
signiﬁcant. Mean number of AEDs before and after implantation in
the responder and non-responder was 3 (range of 2–5 for the
responders and 2–4 for the non-responders). These results,
although based on small amount of patients, are in accordance
with data in the literature in which these variables did not appear
to be independent predictors of outcome.7,14–19
3.4. Reported side effects
All patients reported a stimulation-related tingling sensation in
the throat and/or hoarseness, especially during the ramping-up
period. Two patients reported a painful sensation in the left neck or
ear during stimulation at 2 and 2.25 mA, respectively. Other
stimulation parameters for both patients were: 20 Hz, 500ms,
30 s on/5 min off. One of those patients also complained of a light
dyspnoea when lying on her left side. The dyspnoea was not
continuouslypresentover time,even thoughstimulationparameters
were not adjusted.
One mentally retarded patient, which was considered as a
partial responder at 6 months of follow-up, had a habit to
frequently rotate his generator subcutaneously,which resulted in a
corkscrew shaped lead and ﬁnally to a lead breakage. Consequent-
ly, at 8 months of follow-up, interrogation of his VNS device
showed a very low lead impedance (<200V), which indicated a
short-circuit of his VNS system. Subsequently, the output current
was programmed at 0 mA. As seizure frequency did not increase in
the followingmonths, it was decided not to replace the VNS device.
3.5. SUDEP
One patient died suddenly at the age of 62 after 6 months of
follow-up. She was found at home in asystole with bilateral light-Fig. 3. Percentage of patients programmed at different stimulation outputs at
maximal follow-up.
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after receiving emergency care at home, but she died shortly after.
No speciﬁc cause of death was identiﬁed on autopsy. This case was
considered as a ‘sudden unexpected death in epilepsy’ (SUDEP).
4. Discussion
In this retrospective study we evaluated the efﬁcacy, safety and
practical enhancements of the latest commercially available VNS
device, the VNS Therapy Demipulse 103 Model (Cyberonics1,
Houston, USA), in the treatment of patientswith refractory epilepsy.
Demipulse generators seem to have similar efﬁcacy as previous
generators in the treatment of refractory epilepsy. We evaluated
VNS therapy with Demipulse generators after 12 months of
stimulation. Our study yielded a responder rate of 39%. This result
is comparable to the results obtained with previous models of VNS
generators, such as the study by Morris and Mueller, who
described responder rates of 23% at 3 months and 37% at 1 year.12
Other retrospective and prospective studies reported similar or
slightly higher responder rates after at least 1 year of stimulation,
such as 26%,10 48%,7 50%11 or 54%.3 In our study, mean stimulation
output in the responder group was 1.79 mA range (0.75–2.5),
which is similar to results reported by DeGiorgio et al.13
Besides equivalent efﬁcacy, Demipulse generators appeared to
have similar tolerability as previous generators, as no new side
effects were described in our study.1–3,12,13 We report 1 case of
SUDEP and one case in which VNS therapy was stopped due to a
lead breakage. The relationship between VNS and SUDEP has been
subject of research, although no correlations between VNS
treatment and SUDEP were found.8,20–22 Lead breakages were
also reported in previous studies, especially in children en
mentally retarded patients.23,24
Due to reduced generator volume, Demipulse generators are
more easily implanted, which reduces considerably possible
surgery related complications. Earlier versions of the VNS pulse
generator required larger incisions and larger pouches for
implantation; they also brought about more distinct skin
eminences in the pectoral region and some tension on the wound
edges. In order to avoid unaesthetic scars the insertion of the pulse
generator was often performed via an incision on the anterior
axillary line (and in some cases underneath the pectoralis muscle),
which implicated a longer and broader range of dissection and,
hence, more frequent problems of pouch hematoma and pain after
surgery. The pulse generators n8 103 and 104, in virtue of their
small size and weight, do not require such coping strategies. The
short skin incision can be placed directly over the site of insertion
in the pectoral region, and can be aesthetically closed with a
running intradermal suture or with glue. Problems of pouch
hematoma or pain have become virtually eliminated. Moreover, in
our study no single infection of generator or lead implantation site
was reported, although this is the most common observed surgical
complication in published trials with older devices with an
incidence varying around 3%.23,25 Even though cosmetic advan-
tages are not a priority in health care in general, it is worthwhile
noting that epilepsy patients often deal with a lot of prejudice,
which indirectly affects their social and economic integration in
our society. Discrete scars enhance their well being and ameliorate
their daily social life. For this reason cosmetic advantage of
Demipulse must be emphasized.
Besides the surgical and esthetical advantages of smaller
generator volume, Demipulse generators also enhance treatment
and clinical follow-up of patients. First of all, the generator life
projection system displays the end of life (EOL) in exact amount of
years and months in function of programmed parameters and
warns the clinician 6 months ahead to foresee generator
replacement. This is of particular value, as postponing generatorreplacement may result into permanent loss of seizure control.26
Battery life depends on many factors including the generator
model, stimulation parameters, lead impedance and magnet use.
The ﬁrst model developed for human use, Model 100 (2002), had
an expected battery life of 4–8 years. For the second generation of
generators, i.e. Model 101 (2003) battery life increased to 8–12
years. Model 102 and models 103/104 (2007, Demipulse) have
similar life expectancies as model 101. Ideally, future technology
development will allow transcutaneous battery recharge and
render generator replacements unnecessary. This will further
ameliorate quality of life of patients and reduce health care costs.
Another important feature useful for clinicians is the fact that
Demipulse generators are capable of measuring lead impedances in
Ohms, while older models only delivered DC–DC converter codes.
This gives the clinician more accurate information about the good
functioningof theVNSdevice. Lead impedance should varybetween
200V (low impedance) and 7 kV (high impedance). If high
impedance is discovered upon interrogation of the device, a
discontinuity of the lead or ﬁbrosis between the nerve and the
leadmaybe the reason. To checkwhether a leadbreakage is present,
a radiographyorCT scanof theneck canbeperformed. In other cases
a surgical revision of the device may be needed. Demipulse
generators are able to measure lead impedance every 24 h. If the
impedance has reached ‘‘high’’ or ‘‘low’’ values between interroga-
tions at ofﬁce visits, a warning message will be displayed when
interrogating thedevice. For themoment, thedevicedoesnot inform
the clinician about the exact date/h on which lead impedance
changed. This element could be useful to correlate with certain
potentially harmful events, such as an important head or neck
trauma which could explain breakage of the lead. In our study, one
mentally retarded patient, showed a very low impedance (<200V),
which indicated a short-circuit of his VNS device.
Despite the fact that VNS therapy as a treatment for epilepsy
has proven to reduce signiﬁcantly health care utilisation and its
related costs.27,28 Demipulse generators are not reimbursed in all
countries. In addition to equal efﬁcacy and tolerability in
comparison with older devices, Demipulse generators have better
surgical characteristics and improve clinical follow-up of patients
treatedwith VNS. Future studieswith larger amount of patients are
needed to conﬁrm improved capacities of Demipulse VNS devices,
which hopefullywill lead to reimbursements of the newmodel 103
in all concerned countries.
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